Compound Radar

Nuvalent Inc (NUVL) Stock Analysis

United States · Healthcare / Biotechnology

Price $123.96
Market cap $9.81B
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

34
34/100 Avoid
  • Financial Health 70
  • Profitability 45
  • Business Quality 50
  • Balance Sheet 65
  • Cash Flow 40

Why this rating?

Health 34/100 — Avoid

Strongest Financial Health 70/100
Softest Cash Flow 40/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Nuvalent Inc (NUVL) is a Biotechnology company in the Healthcare sector. Compound Radar rates Nuvalent Inc 34/100 (Avoid) due to solid business quality.

Investment profile

  • Quality Moderate
  • Balance Sheet Unknown

Financial highlights

Valuation

  • Forward P/E -30.85

Profitability

  • Gross Margin 0.0%
  • Operating Margin 0.0%
  • Net Margin 0.0%
  • ROE -41.2%

Financial strength

  • Cash $1.29B
  • Debt $0.00
  • Net Cash $1.29B
  • Free Cash Flow $-180.43M
  • Current Ratio 16.14

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Nuvalent Inc (NUVL).

View Methodology & FAQ →